Breaking News

EMA suspends generic drugs after finding flawed studies; insurance coverage is a big challenge for personalized medicine

  

 

Pharmalot Ed Silverman

STAT+: European regulator suspends generic drugs after finding flawed studies

By Ed Silverman

Adobe

Generic drugmakers that relied on Synchron testing must now provide alternative data to demonstrate bioequivalence.

Read More

STAT+: 'No real clear path': Insurance coverage for cutting-edge diagnostics remains a major challenge for personalized medicine

By Jonathan Wosen

Adobe

Securing payment for new diagnostics remains a major hurdle to turning personalized medicine’s splashy promises into reality.

Read More

STAT+: Up and down the ladder: The latest comings and goings

By Ed Silverman

Alex Hogan/STAT

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Read More

Friday, May 20, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments